TY  - BOOK
AU  - Alvarez,Ricardo H.
AU  - Cortés,Javier
AU  - Mattos-Arruda,Leticia De
AU  - Falzon,Mary
AU  - Fasolo,Angelica
AU  - Gandy,Michael
AU  - Gianni,Luca
AU  - Harbeck,Nadia
AU  - Piccart,Martine
AU  - Zambelli,Stefania
AU  - Zardavas,Dimitrios
ED  - SpringerLink (Online service)
TI  - Handbook of HER2-targeted agents in breast cancer
SN  - 9781907673948
AV  - RC254-282 
U1  - 616.994 23
PY  - 2013///
CY  - Tarporley
PB  - Springer Healthcare Ltd., Imprint: Springer Healthcare
KW  - Medicine
KW  - General practice (Medicine)
KW  - Internal medicine
KW  - Oncology
KW  - Primary care (Medicine)
KW  - Pharmacotherapy
KW  - Medicine & Public Health
KW  - Primary Care Medicine
KW  - General Practice / Family Medicine
KW  - Internal Medicine
N1  - Introduction and background biology -- HER2 testing -- HER2-positive breast cancer: adjuvant and neoadjuvant therapy -- HER2-positive metastatic breast cancer: first-line treatment -- HER2-positive metastatic breast cancer: second-line treatment -- Emerging targeted agents for HER2-positive breast cancer
N2  - Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women worldwide, accounting for nearly a quarter of the total new cancer cases each year.  Of these cases, approximately  15–25% overexpress HER2, a transmembrane RTK kinase that is associated with aggressive tumor growth and poor outcomes.  However, in the past decade, survival rates of patients with HER-positive breast cancer have significantly improved due to increased screening, HER2 testing, and breakthrough HER2-targeted drug therapies. Handbook of HER2-Targeted Agents in Breast Cancer  provides oncologists, primary care physicians, trainees and other healthcare providers with a concise, accessible, and up-to-date survey of the field, including a review of our current understanding of the biology of the HER2 pathway and the rationale for targeting it in early-stage and advanced breast cancer, an overview of HER2-testing, and evidence-based discussions of available HER2-targeted regimens in the adjuvant and metastatic settings
UR  - http://dx.doi.org/10.1007/978-1-907673-94-8
ER  -